4月2日 - ** 制药商 Abeona Therapeutics ABEO.O 股价上涨 2.07% 至 4.67 美元
** 该公司称已将纽约长老会/哥伦比亚大学欧文医疗中心增列为其基因疗法Zevaskyn的治疗中心，从而扩大了纽约和东北部地区的治疗范围
** 该中心是公司第五个合格的治疗中心
** Zevaskyn是唯一获准用于隐性萎缩性表皮松解症成人和儿童伤口治疗的基因疗法，隐性萎缩性表皮松解症是一种罕见的遗传性皮肤病，会导致严重的水疱和难以愈合的伤口 - ABEO
** 称该疗法使用患者自身的皮肤细胞，经过修饰后可恢复缺失的 VII 型胶原蛋白，从而将皮肤层粘合在一起
** 2025年，ABEO股价下跌了5%以上
(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.